The compound advanced to a phase II trial in
benign prostatic hyperplasia, but it was terminated due to difficulty in measuring prostate size, the trial's primary endpoint.[4]
It was also tried in a study to improve quality of life in patients with
prostate cancer. Although it did not cause progression of the disease and increased
lean body mass, the drug did not improve sexual function.[3]
^Yi P, Rehmel JF, Cassidy K, Hadden C, Campanale K, Patel N, Johnson J (December 2012). "Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans". Drug Metabolism and Disposition. 40 (12): 2354–2364.
doi:
10.1124/dmd.112.047613.
PMID22961682.
S2CID6942291.
^Noey EL, Yang Z, Li Y, Yu H, Richey RN, Merritt JM, et al. (June 2017). "Origins of Regioselectivity in the Fischer Indole Synthesis of a Selective Androgen Receptor Modulator". The Journal of Organic Chemistry. 82 (11): 5904–5909.
doi:
10.1021/acs.joc.7b00878.
PMID28467062.